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cis-cleavageintensive investigation for its enzymatic activities and its roles in HCV virus
replication, little is known about the internal processing of NS3. Here we show that single mutations at P1
position of the NS3/4A junction lead to alternative cleavages. Among the multiple novel cleavage products
observed, there were two predominant species of about 12 kDa (p12) and 67 kDa (p67). This p12 species
consists of the NS4A and about a 6 kDa long C-terminal region of NS3 and forms a complex with NS3. The
remaining NS3 corresponds to the p67 species. This alternative cleavage is an NS3 protease-mediated intra-
molecular event and more interestingly can also be induced with low concentrations of one NS3 protease
inhibitor examined. Our results led us to propose a model explaining the alternative cleavage observed and
its functional role.
© 2008 Elsevier Inc. All rights reserved.IntroductionHCV is an enveloped, positive-strand RNA virus that belongs to
hepacivirus genus of the ﬂaviviridae family. This ﬂaviviridae family
includes two more genera, pestivirus (such as bovine viral diarrhea
virus, BVDV) and ﬂavivirus (Choo et al., 2002; Choo et al., 1991; Kato et
al., 1990; Takamizawa et al., 1991). The HCV genome is about 9600
bases long and translated into a polyprotein of about 3000 amino
acids through a single open reading frame (ORF). Subsequently, this
polyprotein undergoes a series of co- and post-translational cleavages
by viral and host cell proteases to yield at least ten proteins: three
structural proteins (C, E1 and E2) and seven nonstructural proteins p7,
NS2, NS3, NS4A, NS4B, NS5A and NS5B. In addition, F protein
(frameshift protein) or ARFP (alternate reading frame protein) has
been proposed to be generated from an overlapping ORF in the core
(C) protein coding sequence, (Xu et al., 2003; Walewski et al., 2001;
Varaklioti et al., 2002). The roles of these proteins in viral replication
have been recently reviewed by Dubuisson (2007).
NS3 is a multifunctional protein. The carboxy-terminal domain of
NS3 harbors an ATPase/helicase activity which is capable of unwind-
ing double stranded nucleic acids (Kim et al., 1995). The amino-
terminal domain of NS3 possesses a serine-type protease activity that
forms a stable heterodimeric complex with NS4A, a protease cofactor
(Bartenschlager et al., 1994; Failla, Tomei, and De Francesco, 1994; Lin
et al., 1994). This viral encoded protease activity is responsible for a
cis-cleavage at the NS3/4A junction and trans-cleavages at NS4A/4B,
NS4B/5A and NS5A/5B junctions. Note, the substrate cleavage sites arel rights reserved.designated as P6–P5–P4–P3–P2–P1–P1′–P2′–P3′–P4′ where the scis-
sile bond is between P1 and P1′. The corresponding substrate binding
sites in the enzyme are called as S6–S5–S4–S3–S2–S1–S1′–S2′–S3′–
S4′ according to the nomenclature of Schechter and Berger (1967). A
sequence alignment of the cleavage site ﬂanking regions has revealed
three conserved positions: an acidic residue at P6 position for all four
cleavage sites; Thr at P1 of the NS3/4A cis-cleavage site and Cys at P1
of trans-cleavage sites; and Ser at P1′ position of all sites except for Ala
at P1′ of the NS4A/4B site of several Asian subtypes. Extensive
mutagenesis studies have been conducted around the cleavage sites
by several groups to understand the substrate speciﬁcity of the NS3
protease. Mutations at the trans-cleavage sites often led to disap-
pearance of the cleavage products. In contrast, mutations at the NS3/
4A cis-cleavage site have been rarely associated with an inhibition of
the cis-cleavage contributing to the belief that this cleavage has low
substrate speciﬁcity (Bartenschlager et al., 1995; Kolykhalov, Agapov,
and Rice, 1994; Leinbach et al., 1994).
We explored the effect of four single mutations at P1 position of
the NS3/4A junction in an in vitro translation system. Unexpectedly,
the NS3/4A cleavage was impaired for a mutation that has been
previously reported as having little effect. Moreover, in addition to
signiﬁcantly blocking the NS3/4A cleavage, the remaining three single
mutants cleaved NS3 at a different site resulting in a C-terminal
cleavage product that is a few kDa larger than NS4A and an N-terminal
product, a few kDa smaller than NS3. This alternative cleavage event is
also observed for the wild type polyprotein in the presence of low
concentrations of an NS3 protease inhibitor. The observed alternative
cleavage event was further conﬁrmed in cells expressing NS3–4A
alone or harboring HCV subgenomic replicon. Finally, the functional
role of the alternative cleavage event is discussed.
Fig. 2. Altered processing of NS3–4A precursors carrying mutations at P1 position of the
NS3/4A cleavage site. In vitro transcription and translation were performed with a
plasmid encoding NS3–4A (lane 1), NS3–4A/T631R (lane 2), NS3–4A/T631V (lane 3),
NS3–4A/T631Y (lane 4) or NS3–4A/T631I (lane 5) precursor. The reaction products were
subjected to immunoprecipitation with mouse anti-NS3 antibody. These immunopre-
cipitates were resolved on 10% (A) or 10–20% (B) Tris–HCl gel followed by immunoblot
with mouse anti-NS3 (A) or mouse anti-NS4A (B) antibody. HCV speciﬁc protein and IgG
bands are labeled on the right. The other possible alternative cleavage products are
labeled with asterisks. Molecular markers are shown on the left in kDa units.
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Inhibition of the cis-cleavage by P1 position mutations
In order to study the effect of P1 mutations on the NS3/4A cis-
cleavage, we changed the codon of 631 in a plasmid expressing the
wild type NS3–4A precursor (designated as pNS3–4A) from
encoding naturally occurring threonine (T) to encoding arginine
(R), valine (V), tyrosine (Y) or isoleucine (I). The resulting plasmid was
called pNS3–4A/T631R, pNS3–4A/T631V, pNS3–4A/T631Y or pNS3–
4A/T631I (Fig. 1). These mutations were chosen based upon previous
reports of their having an impact (T→R, T→Y, and T→ I) or not having
an impact (T→V) on the NS3/4A cleavage efﬁciency (Bartenschlager et
al.,1995; Kolykhalov, Agapov, and Rice,1994; Leinbach et al.,1994). The
wild type NS3–4A precursor and the mutant NS3–4A precursors were
made via in vitro transcription and translation from the plasmids.
Following immunoprecipitation with anti-NS3 antibody, the viral
proteins were resolved on SDS/PAGE and immunoblotted with anti-
NS3 (Fig. 2A) or anti-NS4A (Fig. 2B) antibody. As previously reported,
the wild type precursor was efﬁciently cleaved showing a faint large
band of∼80 kDa (Fig. 2A, lane 1), a strong large band of 73 kDa (Fig. 2A,
lane 1), and a strong small bandof∼6 kDa (Fig. 2B, lane 1), representing
the uncleaved precursor (NS3–4A), C-terminal cleavage product (NS3)
and N-terminal cleavage product (NS4A), respectively. Three of the
four mutations, T631R, T631Y, or T631I, signiﬁcantly decreased the
NS3/4A cleavage efﬁciency leading to accumulation of a large amount
of NS3–4A precursor (Fig. 2A, compare lanes 2, 4, and 5 to lane 1). As
expected, cleavage products (NS3 and NS4A) were absent with the
T631R or T631Ymutant and small amounts of these cleavage products
were observed with the T631I mutant (Figs. 2A, B, compare lane 2, 4,
and 5 to lane 1). As for the T631V mutant, immunoblot analysis with
anti-NS3 antibody showed no effect on the NS3/4A cleavage efﬁciency
(Fig. 2A, lane 3). However, an increased NS3–4A to NS4A ratio was
detectedwith anti-NS4A antibody (Fig. 2B, lane 3)which indicated that
T631V mutation also impaired the cis-cleavage efﬁciency at the NS3/
4A junction. In order to further understand the experimental
observations, interaction energies were calculated for different P1
mutants with the amino acids in S1 pocket of NS3 protease. Calculated
interaction energy of the V631/sidechainwas −4.1 kcal/mol while that
of T631 (wild type) was −6.1 kcal/mol. These results suggest a tighter
binding of T631 sidechain, and thereby, more efﬁcient cleavage of the
wild type precursor which supports the experimental observation.
More favorable interaction energy of T631 sidechain resulted from the
hydrogen bonding interaction betweenhydroxyl of T631 sidechain and
the backbone oxygen of T155 (Fig. 7). Our computations showed that
the other T631mutations studied, I, Y and R required a conformational
change in the protein to be able to accommodate larger sidechains ofFig. 1. A schematic representation of the expression plasmids: HCV NS3 and NS4A are
shown as boxes. The positions of the mutations are marked with asterisks. Amino acid
changes and their positions are written below the asterisks. Location of the c-myc tag
inserted between the 29th and 30th amino acid residues upstream of the NS3/4A cis-
cleavage site is indicated with a solid triangle. Plasmid names are written on the left.these amino acids. Obviously, such substrates will be less favorable
than T or V for the cis-cleavage reaction to occur. Among these
three mutants, I has the smallest sidechain and it can be
accommodated with a conformational change in F154 and L135.
On the other hand, Y and R required conformational changes that
spread well beyond the active site which explains more pronounced
NS3/4A cleavage impairment with T631Y or T631R mutations
observed experimentally (Figs. 2A, B, compare lane 5 to lane 2
and 4). We conclude that P1 mutations studied at the NS3/4A
junction decrease the cis-cleavage efﬁciency, the extent of which
varies among different mutants.
Existence of the alternative cleavage in P1 site mutants
Careful examination of the cleavage products detected with anti-
NS4A and anti-NS3 antibodies revealed an interesting phenomenon,
viz., reduction in cleavage products (NS3 and NS4A) and accumula-
tion of the precursor were accompanied by appearance of two new
species. One new species was about 6 kDa smaller than NS3 (p67,
Fig. 2A) and the other about 6 kDa larger than NS4A (p12, Fig. 2B).
We propose that p12 and p67 are products of an alternative cleavage
at a site that is 6 kDa upstream of the known NS3/4A cleavage site
(Fig. 3A).
In order to test our hypothesis, a new plasmid, pNS3–4A/T631R/
c-myc, was constructed by inserting a ten-amino-acid tag (c-myc)
29 amino acids upstream of the known NS3/4A junction in the
pNS3–4A/T631R plasmid (Fig. 1). Should our hypothesis be correct,
the products made from this pNS3–4A/T631R/c-myc plasmid would
Fig. 3. Characterization of p12. (A) Schematic representation of the alternative cleavage at the C-terminus of NS3 that leads to production of p12 and p67. (B) Detection of p12 with c-
myc insertion. In vitro transcription and translation were performed with a plasmid encoding the NS3–4A (lane 1), NS3–4A/T631R (lane 2), or NS3–4A/T631R/c-myc (lane 3)
precursor. Reaction products were subjected to immunoprecipitation with mouse anti-NS3 antibody. The immunoprecipitates were resolved on 10% (upper panel) or 10–20% (lower
panel) Tris–HCl gel followed by immunoblot with rabbit anti-NS3 (upper panel) or mouse anti-NS4A (lower panel) antibody. The molecular markers are indicated on the left in kDa
units and HCV speciﬁc proteins are labeled on the right.
Fig. 4. Characterization of the alternative cleavage event. Dependence of p12 production
on the NS3 proteolytic activity was examined by in vitro transcription and translation of
plasmids encoding NS3–4A (lane 2), NS3–4A/T631R (lane 3) or NS3–4A/T631R/S139A
(lane 4) precursor. The possibility of trans-cleavage was explored by in vitro
transcription and translation of two plasmids together that encoded NS3–4A/T631R/
S139A and NS3–4A precursor (lane 5). Reaction products were subjected to
immunoprecipitation with mouse anti-NS3 antibody. The immunoprecipitates were
resolved on 10–20% Tris–HCl gel followed by immunoblot with anti-NS4A antibody. The
molecular markers are indicated on the left in kDa units and HCV speciﬁc proteins are
labeled on the right.
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products made from pNS3–4A/T631R plasmid (Fig. 3A). Following in
vitro transcription and translation of pNS3–4A, pNS3–4A/T631R, and
pNS3–4A/T631R/c-myc, the products were analyzed as described
before. Due to the insertion of c-myc tag, a precursor slightly larger
than NS3–4A, labeled as NS3–4A/c-myc, was detected among the
products made from pNS3–4A/T631R/c-myc (compare lanes 2 and 3 in
the top panel of Fig. 3B). However, the N-terminal product made from
pNS3–4A/T631R/c-mycmigrated to the sameposition as p67 (compare
lanes 2 and 3 in the top panel of Fig. 3B), and more importantly, its
C-terminal cleavage product (labeled as p12/c-myc) migrated slower
than p12 (compare lane 2 and 3 in the bottom panel of Fig. 3B). These
results conﬁrmed our hypothesis that p12 is indeed derived from an
alternative cleavage site located upstream of the known NS3/4A
junction in the C-terminal region of NS3. Thus far, our attempts have
been unsuccessful in identifying this alternative cleavage site by
introducing single mutations at the locations that were around 6 kDa
upstream of the NS3/4A junction and also most closely matched with
the consensus cleavage sequences.
In addition to being a product derived from an alternative cleavage
within the C-terminal portion of NS3, p12 forms a complex with NS3
because p12was precipitatedwith an anti-NS3 antibody (Fig. 2B) even
though this same anti-NS3 antibody failed to detect p12 when used
for immunoblot analysis (data not shown).
Dependence of the alternative cleavage on NS3 protease activity
After having demonstrated that p12 is an alternative cis-cleavage
product of the single mutant NS3–4A precursor, we further investi-
gated if this cleavage event was NS3 protease mediated and whether
p12 can be produced through trans-cleavage. Addressing the former,
the catalytic S139 was mutated to an alanine (pNS3–4A/T631R/S139A,
Fig. 1). This mutation has been reported to completely abolish the
proteolytic activity of the NS3 protease (Bartenschlager et al., 1993;
Grakoui et al., 1993; Hijikata et al., 1993). In vitro transcription and
translationwere performed using each plasmid encoding the NS3–4A,
NS3–4A/T631R, or NS3–4A/T631R/S139A precursor. Next, in order to
explore the possibility of p12 production through trans-cleavage, in
vitro transcription and translation were performed using plasmids
that encoded the NS3–4A/T631R/S139A and NS3–4A precursor,
together.The S139A mutant precursor did not produce p12 (Fig. 4, lane 4)
and supplying NS3 protease in trans did not rescue the alternative
cleavage event (Fig. 4, lane 5). These results demonstrated that the
alternative cleavage is NS3 protease mediated and it is an intra-
molecular event (cis-cleavage).
Impact of protease inhibitors on the alternative cleavage
We have shown that the alternative cleavage of the NS3–4A/T631R
mutant is an NS3 protease dependent intra-molecular event. A dose-
dependent reduction of the alternative cleavage products, p12 and
Fig. 5. Effect of NS3 protease inhibitor on the alternative cleavage. Effect of HCV NS3 protease inhibitor on the production of p12was examined by in vitro transcription and translation
of the plasmid encoding the NS3–4A or NS3–4A/T631R precursor (A), or encoding the NS3–5B full-length precursor (B) in the absence or presence of varying concentrations of an HCV
NS3 protease inhibitor (PI). The reaction products were subjected to immunoprecipitationwith mouse anti-NS3 antibody and immunoprecipitates were resolved on 10–20% Tris–HCl
gel followed by immunoblot with rabbit anti-NS3 antibody (upper panels in A and B) or with mouse anti-NS4A antibody (lower panels in A and B). Molecular markers are labeled in
kDa units on the left and HCV speciﬁc proteins on the right.
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with their NS3 protease-dependent nature (Fig. 5A, lanes 5–8).
However, the appearance of p12 from the wild type NS3–4A precursor
in the presence of an NS3 protease inhibitor was a surprising
observation (Fig. 5A, lanes 1–4). This phenomenon was more
pronounced when the proteins were made from a plasmid encoding
the entire NS3–5B polyprotein (Fig. 5B). In the absence of the protease
inhibitor, a small amount of p12was detectedwhich indicated that the
alternative cleavage occurred normally albeit inefﬁciently (Fig. 5B,
lane 1). As the concentration of the protease inhibitor was increased,
the amount of p12 increased initially and then reduced in a dose-
dependent fashion (Fig. 5B, lanes 2–4). Implications of this ﬁnding will
be discussed in the following section.
Existence of p12 in cells
Appearance of p12 from the NS3–4A/T631R mutant was further
investigated in the cells transiently transfected with the plasmid
expressing either NS3–4A/T631R mutant or the wild type NS3–4A
precursor (Fig. 6A). As expected, processing of the wild type NS3–4AFig. 6. Examination of the existence of p12 in cells. (A) Huh-7 cells were transfectedwith
pCL-neo (the vector used to construct the plasmids, labeled as Mock), pNS3–4A or
pNS3–4A/T631R as indicated above each lane. 48 h post transfection, cells were lysed
and the lysates were subjected to immunoprecipitation with anti-NS4A antibody. The
precipitates were resolved in Tris–HCl gel, followed by immunoblotting sequentially
with anti-NS4A (bottom) and anti-NS3 (top) antibody. (B) Huh-luc/neo cells were
treated with the NS3 protease inhibitor (PI) at the concentrations indicated for 24 h.
Cells were lysed and the lysates were subjected to immunoprecipitationwith anti-NS4A
antibody. The precipitates were subsequently resolved in Tris–HCl gel, followed by
immunoblotting with anti-NS4A antibody. The molecular markers are indicated on the
left in kDa and HCV speciﬁc proteins bands are labeled on the right.was very efﬁcient and showed only two cleaved products, NS3 and
NS4A (Fig. 6A, lane 1). However, processing of the mutant was altered
resulting in cleavage at the alternative site to produce p12 and some
uncleaved NS3–4A precursor (Fig. 6A, lane 2). The effect of T631R
mutation on the NS3–4A cleavage was less pronounced in cells as
compared to that in the cell-free system (compare lane 2 in Fig. 6A to
lane 2 in Fig. 3B).
The detection of p12 when the entire NS3–5B polyprotein was
produced in the cell-free systemprompted us to examinewhether p12
would also present in the cells harboring a subgenomic HCV-replicon
(Huh-luc/neo cells), particularly upon addition of an NS3 protease
inhibitor. Even though the amount of p12 was much lower than that
seen in the cell-free system, nonetheless, it was also detected in the
Huh-luc/neo cells treated with the protease inhibitor at all doses
except the highest inhibitor concentration used (Fig. 6B). The reason
for attenuation of this phenomenon in cells is not clear but NS3 and
NS4A are membrane-associated proteins and their dynamic organiza-
tion inside the cells is likely to be different from that in the cell-free
system.
Discussion
The NS3–5B polyprotein is cleaved by a serine protease activity
contained in the N-terminal domain of NS3. A distinct temporal
hierarchy of cleavage events has been observed that begins with an
intra-molecular (cis) cleavage at the NS3/4A junction and followed by
intermolecular (trans) cleavages at the rest of the junctions. Unlike
mutations at the trans-cleavage sites, previous studies have shown
that mutations at the cis-cleavage site rarely lead to a reduction in the
amount of NS3 (Bartenschlager et al., 1995; Kolykhalov, Agapov, and
Rice, 1994; Leinbach et al., 1994).
In this study, the processing of several NS3–4A precursor
molecules carrying different P1 site mutations was investigated in
an in vitro transcription and translation system. When the reaction
products were examined with an anti-NS3 antibody, very little NS3–
4A precursor and a large amount of matured NS3 was detected for the
T631V mutant whereas a large amount of NS3–4A precursor and a
small amount of matured NS3 was observed for the rest of the
mutants (Fig. 2A). These results are in agreement with the previous
reports that small hydrophobic residues (such as valine) do not affect
the cleavagewhereas large hydrophobic (isoleucine), uncharged-polar
(tyrosine) or charged (arginine) P1 residues are poorly tolerated
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Leinbach et al., 1994). Unlike previous studies, we also analyzed the
reaction products with an anti-NS4A antibody for detecting the C-
terminal cleavage products. As a result, we observed two novel
phenomena. First, ratio between NS3–4A and the matured NS4A was
signiﬁcantly increased with the T631V mutant (Fig. 2B, compare
lanes 3 and 1) and that demonstrated a reduced cleavage at the NS3–
4A junction. This result suggested that the cis-cleavage at the NS3/4A
site may not be as impervious to P1 mutations as previously
believed. Our in silico analysis of different 631 mutations showed
that valine ﬁts better in the S1 pocket than isoleucine, arginine or
tyrosine which require substantial change in the protein conforma-
tion (Fig. 7). However, calculated interaction energies suggested that
threonine (wild type) still binds better in the S1 pocket than valine.
Although these results need to be conﬁrmed by additional experi-
ments, some of the other P1 mutations may also reduce the NS3/4A
cis-cleavage efﬁciency despite reports that they have no effect on
this event.
Our second unexpected observationwas the appearance of a novel
species, p12 (12 kDa), for three of the four mutants studied (Fig. 2B,
lanes 2, 4 and 5). Further studies revealed that p12 is the product of an
alternative cleavage of NS3–4A precursor at a previously unknown site
that is located within the C-terminal part of the precursor (Fig. 3). This
cleavage is NS3 protease-mediated and an intra-molecular event
(Fig. 4). A couple more species in addition to p12 and p67 were also
detected which suggested the possibility of alternative cis-cleavage
events at other novel sites within the C-terminal part of NS3 (Fig. 2,
labeled with asterisks).Fig. 7. (A) 3D structure of the NS3/4A complex (1CU1). α-helices are shown with red colo
displayed in green color and amino acids at the C-termini of the cleavage product are show
mutant: Y631 and S1 pocket.Although published literature includes several reports of
internal cleavages of HCV NS3, these cleavages did not result
from mutations at the NS3/4A junction (Gallinari et al., 1999; Kou
et al., 2007; Shoji et al., 1999; Wolk et al., 2000; Yang et al., 2000).
In addition, to the best of our knowledge, there is no prior report
of a cleavage product of 12 kDa. Such results can be explained by
our aforementioned observations where p12 was almost undetect-
able with the wild type precursors and observed with only certain
P1 mutants. Moreover, our observations are reminiscent of what
has been reported for the mutants at the NS4A/4B junction of HCV
(Kolykhalov, Agapov, and Rice, 1994). As a consequence of blocking
the NS4A/4B cleavage by the mutations, an alternative cleavage
occurred in the NS4B region producing p10 and p21. This p10
consists of NS4A and the N-terminal portion of NS4B while p21
was the remaining C-terminal fragment of NS4B. Dependence of
this observation on NS3 protease is yet to be studied. A similar
phenomenon is also reported for subtilisin which is another serine
protease (Kraut, 1977).
The appearance of p12 in the wild type NS3–5B transcription and
translation reaction in the presence of lower concentration of NS3
protease inhibitor is another intriguing phenomenon that has not
been reported previously. The mechanism behind this appearance of
p12 is yet to be understood. One plausible explanation can be
derived from the recent discovery showing that both NS2 and NS5A
function as homodimers (Lorenz et al., 2006; Tellinghuisen,
Marcotrigiano, and Rice, 2005). Should functional NS3 also be an
oligomer as it has been reported recently (Sikora et al., 2008),
inhibitor binding in the active site of one subunit might alter ther, β-strands with cyan color and zinc ion as a magenta sphere. NS4A amino acids are
n with magenta color. (B) T631 and S1 pocket. (C) Computational model of the T631Y
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NS3/4A junction and facilitating the alternative cleavage as observed
with P1 mutations. This possibility would involve an NS3 inhibitor in
low concentrations. As the NS3 inhibitor concentration is increased,
both the active sites present in the oligomer will be occupied leading
to a complete inhibition of the protease, disappearance of p12,
accumulation of higher molecular weight precursors, and reduction
of mature NS3 and NS4A.
The alternative cleavage patterns of HCV NS3 are yet to be
understood. In addition to the aforementioned reports of internal
cleavages, several different internal cleavage events have been
documented in literature, such as, NS3a (49 kDa) and NS3b (23 kDa)
derived from a cleavage within NS3 helicase domain in 293T and
insect cells (Shoji et al., 1999); NS3a–1 of 44 kDa and NS3a–2 of 41 kDa
originating from two cleavages within NS3 helicase domain in several
mammalian cells (Yang et al., 2000); 27 and 40 kDa products arising
presumably from breakdown of NS3–4A precursor stably expressed
in UTA-6 cell line (Wolk et al., 2000); a 47 kDa internal cleavage
product found in NS3–4A expression bacterial extract (Gallinari et al.,
1999); and, several NS3 internal cleavage products ranging 27 to
35 kDa in size detected in Huh-7 cells expressing both NS3 and NS4A
(Kou et al., 2007). Several factorsmay have contributed to the different
HCV NS3 internal cleavage patterns reported, such as, differences in
mechanisms (host vs. NS3 protease mediated or mutation induced),
viral strains, contexts of the proteins, systems for protein expression,
etc. Different detection methods could have also added to the
variability of HCV NS3 internal cleavage patterns reported, for
example, locations of the recognition epitopes where antibodies
are used.
Several reports have proposed the functional role of different
alternative cleavages within the NS3 protein, such as, modulation of
NS3 helicase (Gallinari et al., 1999; Shoji et al., 1999; Yang et al., 2000).
Unlike previous studies, we have described alternative cleavages
within NS3 that are induced by single mutations at the P1 position of
NS3/4A junction. The alternative cleavage event is inversely related to
the cleavage at the NS3/4A junction, i.e., lesser the normal cleavage
products of NS3 and NS4A, more the p12 (Fig. 2). Finally, this
alternative event can also be induced with low concentrations of an
NS3 protease inhibitor. We believe that the function of the alternative
event is to restore the dynamic organization of the NS3 and NS4A
complex.
Structural analysis of NS3 has shown that binding of the NS4A
peptide induces conformational changes in the NS3 protease. The
most signiﬁcant change occurs around the N-terminal 28 residues of
the protease which are unfolded in the unbound state. These
residues fold into a β-strand and an α-helix upon binding of the
NS4A peptide. The β-strand of NS4A is sandwiched between two β-
strands of the N-terminal subdomain resulting in an eight-stranded
β-barrel (Kim et al., 1996; Love et al., 1996; Yan et al., 1998). In a
most recent study, a model was proposed for the dynamic
organization of NS3 and NS4A complex (Brass et al., 2008). Based
on the model, it is after processing at the NS3/4A site that the N-
terminal segment of NS4A is able to insert into the membrane and
position the central segment of NS4A to incorporate into the NS3
protease, forming a stable complex. A lack of amino acid variability
at the P1 site among different HCV genomes available in the
database further emphasizes the importance of cleavage at the NS3/
4A site. In order to adapt to the unfavorable instance where cleavage
at the NS3/4A junction is hindered, the virus, perhaps, has evolved
an alternative approach to release NS4A and restore the organization
of NS3 and NS4A complex by scanning the sequence upstream of the
known NS3/4A junction and choosing a less optimal site to cleave.
The evidence that p12 forms a stable complex with NS3 is consistent
with this hypothesis.
Detection of p12 in the replicon cells in the presence of lower
concentrations of an NS3 protease inhibitor also supports thishypothesis. The current studies, however, are limited to one strain
in genotype 1b and this hypothesis needs to be examined with
different HCV genotypes.
Materials and methods
Reagent and antibody
Rabbit anti-NS3 antibody was a kind gift from Dr. Ralf Bartens-
chlager (Heidelberg, Germany). Mouse anti-NS4A antibody andmouse
anti-NS3 antibody were purchased from Biodesign International (ME,
US). All secondary antibodies were purchased from Santa
Cruz Biotechnology (CA, US). NS3 protease inhibitor [PI, (1R,2S)-1-
((2S,4R)-1-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanoyl)-4-
(7-methoxy-2-phenylquinolin-4-yloxy)pyrrolidine-2-carboxamido)-
2-vinylcyclopropanecarboxylic acid] was synthesized by following
published literature (Boehringer Ingelheim,WO Patent 00/09543) and
the EC50 value against HCV replicon (genotype 1b) is ∼2 μM.
Plasmid construction
DNA fragment corresponding to the NS3–NS4A precursor was
ampliﬁed by PCR with Vent DNA polymerase (New England Biolab)
from the plasmid template pFKi389NS3–3′/WT (licensed from
ReBLikon, Schriesheim, Germany) (Lohmann et al., 1999). The NS3–
4A precursor with T631R, T631V, T631Y or T631I mutation was
introduced by overlapping PCR (Ho et al., 1989). The PCR products
were cloned in frame into NheI and EcoRI restriction sites of pCL-neo
mammalian expression vector (Promega, Madison, WI) downstream
of T7 promoter to obtain pNS3–4A, pNS3–4A/T631R, T631V, T631Y or
T631I. The double mutant (pNS3–4A/T631R/S139A) was generated by
overlapping PCR with S139A point mutation from pNS3–4A/T631R
template. NheI/EcoRI fragment encoding the NS3–4A precursor in
pNS3–4A was replaced with the PCR product encoding the NS3–4A/
T631R/S139A precursor to obtain pNS3–4A/T631R/S139A. The con-
struct, pNS3–4A/T631R/c-myc was also generated by overlapping PCR.
Brieﬂy, PCR fragments containing C-myc sequence (5′gaacaaaaact-
catctcagaagaggatctg) were generated by using pNS3–4A/T631R as the
template with one primer pair of 5′ccggaattcatgGCGCCTATTACGGCCT-
ACTCC and 5′cagatcctcttctgagatgagtttttgttcCAGCCTATACAGCAGGGG
and the other primer pair of, 5'gaacaaaaactcatctcagaagaggatctgGGA-
GCCGTTCAAAACGAGG and 5′gctctagattactaGCACTCTTCCATCTCATCG.
These two fragments were then joined to form a full-length fragment
encoding the NS3–4A precursor with c-myc insertion. Finally, this
fragment was cloned in frame to EcoRI and XbaI sites of pCL-neo
vector.
In vitro transcription and translation
Coupled transcription and translation were performed by using
TnT T7 coupled reticulocyte lysate system (Promega, Madison, WI).
The circular plasmid DNA encoding the NS3–4A precursor (wild type
or mutants) was used as the template for the reaction in the absence
or presence of an NS3 protease inhibitor according to manufacturer's
instructions. The resulting products were subjected to immunopreci-
pitation and immunoblot as described below.
The full-length NS3–5B polyprotein was synthesized by 2 steps of
transcription and translation. The plasmid FK I389luc/NS3–3′/ET
(licensed from ReBLikon, Schriesheim, Germany) (Vrolijk et al.,
2003) was linearized with ScaI and was used as the template for in
vitro RNA transcription by following manufacturer's instructions
(5×MEGAscript ® T7 kit, Ambion, Austin, TX). The RNA encoding the
full-length NS3–5B was puriﬁed from the in vitro transcription
reaction mixture and was translated in vitro by using rabbit
reticulocyte lysate translation system (Promega, Madison, WI)
supplemented with 5% of canine pancreatic microsomal membranes.
277X. Hou et al. / Virology 383 (2009) 271–278The resulting products were subjected to immunoprecipitation and
immunoblot as described below.
Cells and transfection
Huh-7 cells and Huh-luc/neo were licensed from ReBLikon GmbH
(Mainz, Germany). Huh-7 cells were derived from human hepatoma.
Huh-luc/neo was generated by transfection of Huh-7 cells with a
genotype 1b subgnomic replicon RNA molecules synthesized in vitro
from the plasmid FK I389luc/NS3–3′/ET followed by G418 selection as
described previously (Vrolijk et al., 2003). Huh-7 cells were main-
tained in a complete medium [Dulbecco's modiﬁed minimal essential
medium (DMEM) (Gibco BRL, Carlsbad, California), 10% fetal bovine
serum (FBS), and 1×nonessential amino acids (Gibco BRL, Carlsbad,
California)] with addition of 100 IU/ml penicillin and 100 μg/ml
streptomycin. Huh-luc/neo was maintained in the same medium plus
0.5 mg/ml of G418 (Gibco BRL, Carlsbad, California).
Transient transfection of the plasmid expressing NS3–4A variants
was performed using FuGENE 6 transfection reagent (Roche, Indiana-
polis, IN) according to the manufacturer's instructions. Brieﬂy, Huh-7
cells were seeded in a 6-well plate at a density of 3×105/well. On the
following day, 1 μg of the plasmid was used for each transfection. Two
days post transfection, cells were lysed in the NBP [50 mM Tris—pH
7.5, 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS supplemented
with protease inhibitors (Complete, Mini, EDTA-free. Roche, Indiana-
polis, IN)].
Treatment of Huh-luc/neo cells was performed as follows. Huh-7
cells were seeded in a 6-well plate at a density of 3×105/well. On the
following day, the protease inhibitor was added and the cells were
lysed in the NBP following 24 h incubation.
Immunoprecipitation and immunoblot analysis
Portions of each in vitro reaction were used for immunoprecipita-
tionwithmouse anti-NS3 antibody pre-adsorbed to protein A-agarose
beads (Invitrogen, San Diego, CA). After rotating at 4 °C overnight, the
beads were washed four times with PBST (PBS plus 0.05% Tween 20)
supplemented with protease inhibitors cocktail (Roche Applied
Science, Indianapolis, IN). The proteins were resolved on a premade
Tris–HCl gel (Bio-Rad, Hercules, CA) in a running buffer consisting of
25 mM Tris Base, 192 mM glycine and 0.1% SDS.
After electrophoresis, the proteins in the gel were transferred to a
membrane (Immun-Blot PVDF/Filter Paper Sandwich, Bio-Rad, Her-
cules, CA). The membrane was blocked in PBST plus 5% dry milk and it
was probed with the ﬁrst antibody (mouse anti-NS4A, 1:2000
dilution; or mouse anti-NS3, 1:1000 dilution, or rabbit anti-NS3,
1:10,000 dilution) in PBST and 3% dry milk. After washing the
membrane three times in PBST, the membrane was probed with the
secondary antibody (goat anti-mouse, 1:5000 dilution or goat anti-
rabbit, 1:5000 dilution) in PBST plus 3% dry milk. The membrane was
washed twice with PBST and another two times with PBS and the
bound antibody was ﬁnally detected by chemiluminescence using ECL
plus (Amersham, Piscataway, NJ).
The lysates from transient transfected cells or Huh-luc/neo cells
were subjected to centrifugation in a microcentrifuge for 15 min at
∼20,000 × g at 40 °C. The supernatants were transferred to a fresh
tube containing protein A beads (Invitrogen, San Diego, CA)
prebound with anti-NS4A antibody. The rest of steps were described
as above.
Computational chemistry
T631/R/Y/I/V mutants were modeled starting from NS3 X-ray
structure (pdb code: 1CU1) (Yao et al., 1999) using MOE2007.09.
Hydrogen atomswere added and the proteinwas solvated by applying
periodic boundary conditions. Wild type protein and 631 mutantswere energy minimized at a constant dielectric of one with the
conjugated gradient method and the MMFF94 force ﬁeld.
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